Pfizer collaborates for Phase III axitinib Asia trial
This article was originally published in Scrip
Pfizer has inked a deal with SFJ Pharma Ltd II, a drug development company that specialises in obtaining regulatory approval for drugs for the Japanese market, to conduct a Phase III clinical study for the investigational agent axitinib in six Asian countries.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"